Newly Arrival Irinotecan Hydrochloride Trihydrate - Temozolomide (TMZ) CAS 85622-93-1 Assay 99.0%~101.0% API Factory High Purity – Ruifu

Manufacturer with High Purity and Stable Quality Supply Temozolomide and Related Intermediates: Temozolomide CAS: 85622-93-1 5(4)-Amino-4(5)-imidazolecarboxamide Hydrochloride CAS: 72-40-2

Chemical Name	Temozolomide
Synonyms	3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
CAS Number	85622-93-1
CAT Number	RF-API29
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C6H6N6O2
Molecular Weight	194.15
Brand	Ruifu Chemical

Item	Specifications
Appearance	White or to Light Pink Powder
Dimethyl Sulphoxide	≤0.50%
Related Substances
The Known Impurity	AIC≤0.10%
Single Impurity	≤0.10%
Rest Related Impurities	≤0.30%
Total Impurities	≤0.30%
Heavy Metals	≤10ppm
Loss on Drying	≤0.50%
Residue on Ignition	≤0.10%
Assay	99.0%~101.0%
Test Standard	Enterprise Standard
Usage	Active Pharmaceutical Ingredient (API)

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation. Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Temozolomide (CAS: 85622-93-1) with high quality, active pharmaceutical ingredient (API). Temozolomide (TMZ) is an oral alkylating agent used to treat Glioblastoma Multiforme (GBM) and Astrocytomas, Metastatic Melanoma. Temozolomide is the first effective orally-taken imidazole and tetrazine-class anticancer drug which belongs to the second generation of an alkylating agent with antitumor activity without liver metabolic activation after oral administration. It is characterized by easily penetration through the blood-brain barrier, good tolerance and being not superimposed with other drugs toxicity, and having synergistic effect with radiotherapy which is suitable for treating malignant glioma recurrence after conventional treatment such as glioblastoma multiforme tumors or degenerative astrocytoma. It is first-line drug for treatment of metastatic melanoma. Temozolomide had been first synthesized by Cancer Research UK Group, and then be transferred to the Schering-Plough Company (United States) for development. The drug is different from the existing Antineoplastic drug. It has a novel chemical structure and belongs to a four-imidazole derivative. Temozolomide does not play a direct role. At physiological pH, it is first quickly converted into active compound MTIC [5-(3-methyl-triazene-1-) imidazole-4-carboxamide] via non-enzymatically way. People think that the cytotoxicity of MTIC is mainly due to its DNA alkylation (methylation) effect. Alkylation mainly occurs in the O6 and N7 position of guanine. Basic and clinical studies of temozolomide have confirmed that it is effective in treating some of the most common glioma cells. In 1999, it has been approved for enter into market in EU and the US wherein the permitted indication in United States is mainly for second-line treatment of glioblastoma multiforme and degenerative star gliomas and approved indications of EU is for treating developing or relapsing glioblastoma multiforme which has already been subject to conventional therapy. The efficacy of temozolomide on treating glioblastoma multiforme has received more recognition in Europe.